Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Naibo Hu"'
Autor:
Guangshuai Teng, Yuhui Zhang, Chenxiao Du, Yan Wang, Naibo Hu, Yingdi Han, Jinyu Ma, Shan Gao, Guangpeng Xiang, Zonghong Shao, Jie Bai
Publikováno v:
Blood. 140:3959-3960
Autor:
Guangshuai Teng, Yuan Zhou, Yuhui Zhang, Naibo Hu, Tong Liu, Yingdi Han, Chao Gao, Lei Zhang, Jie Bai
Publikováno v:
Thrombosis research. 212
Post-polycythemia vera (PV) myelofibrosis (Post-PV MF) is an advanced phase of natural progression of PV. Thrombosis is a major cause of morbidity and mortality in PV; however, the characteristics of thrombosis in post-PV MF have not been characteris
Autor:
Bingyi Wang, Shiqiang Qu, Tiejun Qin, Zhijian Xiao, Naibo Hu, Zefeng Xu, Xiaoyan Du, Xiaoyun Wang, Lijuan Pan
Publikováno v:
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research
BACKGROUND Hypomethylating agents (HMA) are considered the first-line therapy for high-risk myelodysplastic syndromes (MDS). However, as the efficacy and safety of rational dosing regimens are lacking, we evaluated the effectiveness and safety of red
Autor:
Jie Gao, Yudi Zhang, Zhijian Xiao, Dan Wu, Naibo Hu, Wenyu Cai, Y Zhang, Sirui Ren, Zefeng Xu, Bing Li, Huijun Huang, Gang Huang, Jinqin Liu, Lijuan Pan, Lihong Shi, Peihong Zhang, Shiqiang Qu, Jiaxi Zhou, Tiejun Qin, Changlu Xu, Meng Jiao, Robert Peter Gale
Publikováno v:
Blood Cancer Journal
Blood Cancer Journal, Vol 10, Iss 8, Pp 1-12 (2020)
Blood Cancer Journal, Vol 10, Iss 8, Pp 1-12 (2020)
The underlying mechanisms and clinical significance of ineffective erythropoiesis in myelodysplastic syndromes (MDS) remain to be fully defined. We conducted the ex vivo erythroid differentiation of megakaryocytic-erythroid progenitors (MEPs) from MD
Autor:
Shiqiang Qu, Tiejun Qin, Zhijian Xiao, Bing Li, Zefeng Xu, Naibo Hu, Gang Huang, Lijuan Pan, Robert Peter Gale
Publikováno v:
Br J Haematol
We screened 47 subjects with DDX41 variants among 1529 subjects with myeloid neoplasms. The most common germline variants included Splice c.935 + 4A>T, p.T360Ifs*33, p.V152G, p.S217Ifs*4, p.R311* and p.R369*. Except for the p.R369*, no other variants
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6656804b7b8a4e56d4fdab0aaac871dd
https://europepmc.org/articles/PMC9205684/
https://europepmc.org/articles/PMC9205684/
Autor:
Zefeng Xu, Zhongxun Shi, Liwei Fang, Gang Huang, Hongli Zhang, Lijuan Pan, Bing Li, Naibo Hu, Robert Peter Gale, Zhijian Xiao, Huijun Huang, Shiqiang Qu, Tiejun Qin
Publikováno v:
Leuk Lymphoma
Myelodysplastic syndrome (MDS) is a heterogeneous clonal myeloid neoplasm of ineffective hematopoiesis, dysplasia and an increased risk of progression to acute myeloid leukemia (AML) [1]. Although ...
Publikováno v:
Blood. 138:4618-4618
Thrombosis is a major cause of morbidity and mortality in polycythemia vera (PV). Post PV myelofibrosis (MF) is the advanced phase in the natural progression of PV. To explore the risk factors for thrombosis in post-PV MF, clinical characteristics, l
Publikováno v:
Blood. 138:4425-4425
The expression rate of CD38 in acute myeloid leukemia is high. It is reported that the expression of CD38 in myeloid leukemia is stable and can be used as a potential therapeutic target for leukemia. Daratumumab is a therapeutic drug targeting CD38.
Autor:
Naibo Hu, Hongli Zhang, Lijuan Pan, Zhijian Xiao, Bing Li, Y. Cai, Zefeng Xu, D. Liu, Shiqiang Qu, Tiejun Qin, Z. Shi, Yingchi Zhang, Liwei Fang, H. Huang
Publikováno v:
Leukemia Research. 108:106680.18
Autor:
Zhijian Xiao, Shiqiang Qu, Tiejun Qin, Jingya Wang, Naibo Hu, Zefeng Xu, Jinqin Liu, Shuailing Peng, Huijun Huang, Jian Wu, Yue Zhang, Yujiao Jia, Liwei Fang, Zhongxun Shi, Bing Li, Kun Ru, Na Liu, Gang Huang, Hongli Zhang, Lijuan Pan, Zhen Song
Publikováno v:
Genes Chromosomes Cancer
U2AF1 mutations (U2AF1MT) occur commonly in myelodysplastic syndromes (MDS) without ring sideroblasts. The aim of this study was to investigate the clinical and biological implications of different U2AF1 mutation types in MDS. We performed targeted g